Prognostic factors in patients with refractory idiopathic generalized epilepsy

Anxiety and depression symptoms disrupt resting state connectivity in patients with genetic generalized epilepsies

“…This is not surprising, as different studies have consistently reported anxiety, mood, and personality disorders in GGEs, especially JME . In our cohort, the odds ratio of pharmacoresistance with co‐occurrence of anxiety and depressive symptoms was 7.7, in accordance with a recent report of an odds ratio of 6.1 for refractoriness when patients presented a psychiatric disorder (including depression, anxiety, and schizophrenia) . These results are consistent with our recent temporal lobe epilepsy analyses, as the odds ratio of pharmacoresistance with concurrent anxiety and mood disorders was 4.4, reinforcing the hypothesis of common neurobiological mechanisms between epilepsy and psychiatric disorders .…”

“…After examining life trajectories (median = 13 years), we observed that most GGE patients (65%) from our tertiary hospital alternated periods of total seizure control with periods of recurrent seizures; smaller proportions could be classified as Although most of the population-based studies of GGE patients have reported a good response to antiepileptic medications, 22 more recent hospital-based studies have revealed heterogeneity in the seizure outcome of these patients. [23][24][25] Considering the whole period of follow-up in our institution, we identified 19% as pharmacoresistant epilepsy, which is similar to previous studies that estimated 10%-32% as pharmacoresistant. 10,26,27 Unfortunately, only 16.2% of our cohort reached sustainable seizure freedom, whereas most (64.8%) alternated between relapsing and remitting periods.…”

“…Although most of the population‐based studies of GGE patients have reported a good response to antiepileptic medications, more recent hospital‐based studies have revealed heterogeneity in the seizure outcome of these patients . Considering the whole period of follow‐up in our institution, we identified 19% as pharmacoresistant epilepsy, which is similar to previous studies that estimated 10%‐32% as pharmacoresistant .…”

“…10,32 One hypothesis for these findings is that at a younger age, some of these individuals are more likely to have an irregular, impulsive lifestyle, favoring seizures associated with poor treatment compliance and substance abuse, among others stressing factors. 24,25 In contrast, as individuals get older, they may progressively evolve into a more stable and healthy lifestyle, with better AED compliance and ultimately improved seizure control.…”

Juvenile Myoclonic Epilepsy: Focus on the Use of Topiramate (Literature Review and Own Data)

“…В одной из последних работ, посвященных оценке факторов резистентности при ИГЭ, включая и ЮМЭ (А. Gomez-Ibañez и соавт., 2017) [27], основными факторами были ранний возраст дебюта заболевания (до 13 лет), длительное сохранение приступов, сочетание нескольких типов генерализованных приступов, развитие эпилептического статуса, выражен-ная генерализованная и полиспайковая эпилептиформная активность на ЭЭГ, побочные эффекты АЭП, сопутствую-щие психические нарушения. Наиболее значимым факто-ром риска для ЮМЭ в этом исследовании являлись сопут-ствующие психические нарушения.…”